PATENT CLAIM ANALYSIS

Application Number: 15875296
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "183000"]

Abstract:
The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.

Claim (Index 27):
The method of  claim 21 , wherein the pharmaceutical composition can be reconstituted to achieve at least 30 mL of liquid in the total volume of suspension.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 86.0
- Lexical Diversity: 1.45652
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15643724', '15345748', '14972269', '11974068', '14221352']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8497060192972034
- 35 USC 102 Novelty (BERT): 0.6020756359280234
- Combined Prediction Score: 0.8249429809602854
- Mean Citation Score: 528.402086
- Max Citation Score: 540.1749
- Similarity Product: 468.2714534745991

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test